个体患者数据的系统性回顾 COVID-19 感染和疫苗接种相关性血栓性微血管病

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-11-01 DOI:10.1016/j.ekir.2024.07.034

Pujan Moradiya , Priyanka Khandelwal , Rupesh Raina , Ruchi Gupta Mahajan

{"title":"个体患者数据的系统性回顾 COVID-19 感染和疫苗接种相关性血栓性微血管病","authors":"Pujan Moradiya , Priyanka Khandelwal , Rupesh Raina , Ruchi Gupta Mahajan","doi":"10.1016/j.ekir.2024.07.034","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Sporadic cases of atypical hemolytic uremic syndrome (aHUS) have been described in the literature in association with COVID-19 infection and vaccination in adults and pediatric patients. The exact mechanisms underlying COVID-19–associated thrombotic microangiopathies (TMAs) remain incompletely understood. Herein, we present a detailed meta-analysis of the clinical characteristics, outcomes, and management strategies of COVID-19–associated aHUS and thrombotic thrombocytopenic purpura (TTP).</div></div><div><h3>Methods</h3><div>This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses updated guidelines. PubMed was utilized for searching for case reports and series. Adverse outcome at last follow-up was defined as estimated glomerular filtration rate < 30 ml/min per 1.73 m<sup>2</sup> (patients with aHUS), no remission with therapy, or patient death. Data were analyzed using Wilcoxon rank and Chi-square tests.</div></div><div><h3>Results</h3><div>Our analysis cohort included 118 studies reporting on 170 patients. These included 84 cases of aHUS and 86 cases of TTP resulting from COVID-19 infection (<em>n</em> = 92) or vaccination (<em>n</em> = 78). Significantly more cases of aHUS were reported after infection (<em>n</em> = 65) than immunization (<em>n</em> = 19), compared to TTP, where the reverse was true (<em>n</em> = 27 and <em>n</em> = 59, respectively; <em>P</em> < 0.001). In patients with aHUS with stage 3 acute kidney injury (AKI), requirement of kidney replacement therapy (KRT) was seen in three-fourths of the cohort for a median of 15. In patients with TTP, severe COVID-19 infection (<em>P</em> = 0.04) predicted nonremission or death at last follow-up. Administration of i.v., rituximab and caplacizumab were protective (<em>P</em> = 0.03 and <em>P</em> = 0.06, respectively). Immune TTP (iTTP) was reported more often than HUS following mRNA vaccines (81% vs. 58%; <em>P</em> = 0.06).</div></div><div><h3>Conclusion</h3><div>COVID-19 infection and vaccination are a potential trigger for onset or relapse of aHUS and TTP, especially in patients who are not on maintenance complement inhibitors or immunosuppression.</div></div>","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination–Associated Thrombotic Microangiopathy\",\"authors\":\"Pujan Moradiya , Priyanka Khandelwal , Rupesh Raina , Ruchi Gupta Mahajan\",\"doi\":\"10.1016/j.ekir.2024.07.034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Sporadic cases of atypical hemolytic uremic syndrome (aHUS) have been described in the literature in association with COVID-19 infection and vaccination in adults and pediatric patients. The exact mechanisms underlying COVID-19–associated thrombotic microangiopathies (TMAs) remain incompletely understood. Herein, we present a detailed meta-analysis of the clinical characteristics, outcomes, and management strategies of COVID-19–associated aHUS and thrombotic thrombocytopenic purpura (TTP).</div></div><div><h3>Methods</h3><div>This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses updated guidelines. PubMed was utilized for searching for case reports and series. Adverse outcome at last follow-up was defined as estimated glomerular filtration rate < 30 ml/min per 1.73 m<sup>2</sup> (patients with aHUS), no remission with therapy, or patient death. Data were analyzed using Wilcoxon rank and Chi-square tests.</div></div><div><h3>Results</h3><div>Our analysis cohort included 118 studies reporting on 170 patients. These included 84 cases of aHUS and 86 cases of TTP resulting from COVID-19 infection (<em>n</em> = 92) or vaccination (<em>n</em> = 78). Significantly more cases of aHUS were reported after infection (<em>n</em> = 65) than immunization (<em>n</em> = 19), compared to TTP, where the reverse was true (<em>n</em> = 27 and <em>n</em> = 59, respectively; <em>P</em> < 0.001). In patients with aHUS with stage 3 acute kidney injury (AKI), requirement of kidney replacement therapy (KRT) was seen in three-fourths of the cohort for a median of 15. In patients with TTP, severe COVID-19 infection (<em>P</em> = 0.04) predicted nonremission or death at last follow-up. Administration of i.v., rituximab and caplacizumab were protective (<em>P</em> = 0.03 and <em>P</em> = 0.06, respectively). Immune TTP (iTTP) was reported more often than HUS following mRNA vaccines (81% vs. 58%; <em>P</em> = 0.06).</div></div><div><h3>Conclusion</h3><div>COVID-19 infection and vaccination are a potential trigger for onset or relapse of aHUS and TTP, especially in patients who are not on maintenance complement inhibitors or immunosuppression.</div></div>\",\"PeriodicalId\":5,\"journal\":{\"name\":\"ACS Applied Materials & Interfaces\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Materials & Interfaces\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468024924018643\",\"RegionNum\":2,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MATERIALS SCIENCE, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468024924018643","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

文献中描述了成人和儿童患者感染 COVID-19 和接种 COVID-19 疫苗后出现非典型溶血性尿毒症（aHUS）的零星病例。COVID-19相关的血栓性微血管病（TMAs）的确切机制仍不完全清楚。在此，我们对 COVID-19 相关性 aHUS 和血栓性血小板减少性紫癜（TTP）的临床特征、预后和管理策略进行了详细的荟萃分析。本研究遵循《系统综述和荟萃分析首选报告项目》（Preferred Reporting Items for Systematic Reviews and Meta-analyses）最新指南进行。利用 PubMed 搜索病例报告和系列研究。最后一次随访时的不良结局定义为估计肾小球滤过率< 30 ml/min per 1.73 m（aHUS 患者）、治疗无缓解或患者死亡。数据采用 Wilcoxon 秩检验和卡方检验进行分析。我们的分析队列包括 118 项研究，报告了 170 例患者。其中包括 84 例 aHUS 和 86 例由 COVID-19 感染（= 92 例）或疫苗接种（= 78 例）引起的 TTP。感染后的 aHUS 病例（= 65 例）明显多于免疫接种后的病例（= 19 例），而 TTP 病例则相反（分别为 = 27 例和 = 59 例；< 0.001）。在急性肾损伤（AKI）3期的aHUS患者中，四分之三的患者需要接受肾脏替代治疗（KRT），中位数为15天。在TTP患者中，严重的COVID-19感染（=0.04）预示着最后一次随访时将出现不缓解或死亡。静脉注射利妥昔单抗和卡普拉珠单抗具有保护作用（分别为0.03和0.06）。接种 mRNA 疫苗后，免疫性 TTP (iTTP) 的报告率高于 HUS（81% 对 58%; = 0.06）。COVID-19 感染和疫苗接种是 aHUS 和 TTP 发病或复发的潜在诱因，尤其是在未使用补体抑制剂或免疫抑制剂的患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination–Associated Thrombotic Microangiopathy

查看原文本刊更多论文

Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination–Associated Thrombotic Microangiopathy

Introduction

Sporadic cases of atypical hemolytic uremic syndrome (aHUS) have been described in the literature in association with COVID-19 infection and vaccination in adults and pediatric patients. The exact mechanisms underlying COVID-19–associated thrombotic microangiopathies (TMAs) remain incompletely understood. Herein, we present a detailed meta-analysis of the clinical characteristics, outcomes, and management strategies of COVID-19–associated aHUS and thrombotic thrombocytopenic purpura (TTP).

Methods

This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses updated guidelines. PubMed was utilized for searching for case reports and series. Adverse outcome at last follow-up was defined as estimated glomerular filtration rate < 30 ml/min per 1.73 m² (patients with aHUS), no remission with therapy, or patient death. Data were analyzed using Wilcoxon rank and Chi-square tests.

Results

Our analysis cohort included 118 studies reporting on 170 patients. These included 84 cases of aHUS and 86 cases of TTP resulting from COVID-19 infection (n = 92) or vaccination (n = 78). Significantly more cases of aHUS were reported after infection (n = 65) than immunization (n = 19), compared to TTP, where the reverse was true (n = 27 and n = 59, respectively; P < 0.001). In patients with aHUS with stage 3 acute kidney injury (AKI), requirement of kidney replacement therapy (KRT) was seen in three-fourths of the cohort for a median of 15. In patients with TTP, severe COVID-19 infection (P = 0.04) predicted nonremission or death at last follow-up. Administration of i.v., rituximab and caplacizumab were protective (P = 0.03 and P = 0.06, respectively). Immune TTP (iTTP) was reported more often than HUS following mRNA vaccines (81% vs. 58%; P = 0.06).

Conclusion

COVID-19 infection and vaccination are a potential trigger for onset or relapse of aHUS and TTP, especially in patients who are not on maintenance complement inhibitors or immunosuppression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.